Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30980621 | 1.00 | BCHE (0.45) | BCHECNR2CYP2C19CA12CA1 | |
| SCHEMBL22371541 | 1.00 | BCHE (0.45) | BCHECNR2CYP2C19CA12CA1 | |
| SCHEMBL10233481 | 0.93 | CA12 (0.48) | CYP2C19CA12CA1CA2CA9 | |
| SCHEMBL16980508 | 0.90 | CA12 (0.49) | CYP2C19CA12CA1CA2CA9 | |
| SCHEMBL31294842 | 0.89 | CA12 (0.50) | CYP2C19CA12CA1CA2CA9 | |
| SCHEMBL22371611 | 0.86 | MAPT (0.50) | BCHECNR2CYP2C19CA12CA1 | |
| SCHEMBL30693811 | 0.84 | CA12 (0.57) | BCHECNR2CA12CA1CA2 | |
| SCHEMBL25987728 | 0.84 | CA12 (0.57) | BCHECNR2CA12CA1CA2 | |
| SCHEMBL17162067 | 0.84 | CA12 (0.57) | BCHECNR2CA12CA1CA2 | |
| SCHEMBL22371591 | 0.84 | PPARG (0.43) | CYP2C19KDM4EMEN1PABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-115768765-A | Methods and compounds for treating genetic diseases | 设计治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | BCHE 4341/4885CNR2 4730/4885CYP2C19 4881/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | BCHE 4038/4885CNR2 4256/4885CYP2C19 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.